I. POLICY

Lung transplantation may be considered medically necessary for carefully selected patients with irreversible, progressively disabling, end-stage pulmonary disease unresponsive to maximum medical therapy, including, but not limited to one of the conditions listed below.

A lobar lung transplant from a living or deceased donor may be considered medically necessary for carefully selected patients with end-stage pulmonary disease including, but not limited to, one of the conditions listed in Table 1.

Table 1. Conditions and Codes

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilateral bronchiectasis</td>
<td>J47.0, J47.1, Q33.4- for congenital</td>
</tr>
<tr>
<td>Alpha-1 antitrypsin deficiency</td>
<td>E88.01</td>
</tr>
<tr>
<td>Primary pulmonary hypertension</td>
<td>I27.0</td>
</tr>
<tr>
<td>Cystic fibrosis (both lungs to be transplanted)</td>
<td>E84.0, E84.8</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
<td>P27.1</td>
</tr>
<tr>
<td>Postinflammatory pulmonary fibrosis</td>
<td>J84.10</td>
</tr>
<tr>
<td>Idiopathic/interstitial pulmonary fibrosis</td>
<td>J84.112, J84.17</td>
</tr>
<tr>
<td>Sarcoïdosis</td>
<td>D86.0</td>
</tr>
<tr>
<td>Scleroderma</td>
<td>M34.81</td>
</tr>
<tr>
<td>Lymphangiomyomatosis</td>
<td>J84.81</td>
</tr>
<tr>
<td>Emphysema</td>
<td>J43.0, J43.1, J43.2, J43.8, J98.2, J98.3</td>
</tr>
<tr>
<td>Eosinophilic granuloma</td>
<td>C96.6</td>
</tr>
<tr>
<td>Bronchiolitis obliterans</td>
<td>J42, J84.89</td>
</tr>
<tr>
<td>Pulmonary hypertension due to cardiac disease</td>
<td>I27.2, I27.89</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>J44.0, J44.1</td>
</tr>
<tr>
<td>Eisenmenger syndrome</td>
<td>I27.89</td>
</tr>
</tbody>
</table>
Lung or lobar lung retransplantation after a failed lung or lobar lung transplant may be considered **medically necessary** in patients who meet criteria for lung transplantation.

Lung or lobar lung transplantation is considered **investigational** in all other situations, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

### Policy Guidelines

#### General

Potential contraindications subject to the judgment of the transplant center:

1. Known current malignancy, including metastatic cancer
2. Recent malignancy with high risk of recurrence
3. Untreated systemic infection making immunosuppression unsafe, including chronic infection
4. Other irreversible end-stage disease not attributed to lung disease
5. History of cancer with a moderate risk of recurrence
6. Systemic disease that could be exacerbated by immunosuppression
7. Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

#### Policy-specific

8. Coronary artery disease (CAD) not amenable to percutaneous intervention or bypass grafting, or associated with significant impairment of left ventricular function*;
9. Colonization with highly resistant or highly virulent bacteria, fungi, or mycobacteria.

*Some patients may be candidates for combined heart-lung transplantation. See MP – 9.014

Patients must meet United Network for Organ Sharing (UNOS) guidelines for lung allocation score (LAS) greater than zero.

### Lung Specific

Bilateral lung transplantation is typically required when chronic lung infection disease is present, i.e., associated with cystic fibrosis and bronchiectasis. Some, but not all, cases of pulmonary hypertension will require bilateral lung transplantation.
Bronchiolitis obliterans is associated with chronic lung transplant rejection, and thus may be the etiology of a request for lung retransplantation.

**Cross-references:**
- MP- 8.008 Outpatient Pulmonary Rehabilitation
- MP- 9.002 Immune Cell Function Assay
- MP- 9.014 Heart/Lung Transplant

### II. PRODUCT VARIATIONS

This policy is applicable to all programs and products administered by Capital BlueCross unless otherwise indicated below.

BlueJourney HMO*  BlueJourney PPO*  FEP PPO**

*Lung transplantation is covered under Medicare when performed in a facility that is approved by Medicare as meeting institutional coverage criteria. For a list of approved facilities, see: [http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandCompliance/downloads/ApprovedTransplantPrograms.pdf](http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandCompliance/downloads/ApprovedTransplantPrograms.pdf).

**Refer to FEP Medical Policy Manual MP-7.03.07, Lung and Lobar Lung Transplant. The FEP Medical Policy Manual can be found at: [www.fepblue.org](http://www.fepblue.org).

### III. DESCRIPTION/BACKGROUND

A lung transplant consists of replacing all or part of diseased lungs with healthy lung(s). Transplantation is an option for patients with end-stage lung disease. End-stage lung disease may be the consequence of a number of different etiologies. The most common indications for lung transplantation are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), alpha-1 antitrypsin deficiency and idiopathic pulmonary arterial hypertension (IPAH). Prior to the consideration for transplant, patients should be receiving maximal medical therapy including oxygen supplementation or surgical options such as lung-volume reduction surgery for COPD. Lung or lobar lung transplantation is an option for patients with end-stage lung disease despite these measures.

A lung transplant refers to single-lung or double-lung replacement. In a single-lung transplant, only one lung from a deceased donor is provided to the recipient. In a double-lung transplant, both the recipient's lungs are removed and replaced by the donor's lungs. In a lobar transplant, a lobe of the donor’s lung is excised, sized appropriately for the recipient’s thoracic dimensions, and transplanted. Donors for lobar transplant have been primarily living-related donors, with one lobe obtained from each of two donors (e.g., mother and father) in cases where bilateral
transplantation is required. There are also cases of cadaver lobe transplants. Combined lung-pancreatic islet cell transplant is being studied for patients with cystic fibrosis.\(^1\)

Since 2005, potential recipients have been ranked according to the Lung Allocation Score (LAS).\(^2,3\) Patients 12 years of age and older receive a score between 1 and 100 based on predicted survival after transplantation reduced by predicted survival on the waiting list; the LAS takes into consideration the patient’s disease and clinical parameters. In 2010, a simple priority system was implemented for children under the age of 12. Under this system, children under 12 with respiratory lung failure and/or pulmonary hypertension who meet criteria are considered “priority 1” and all other candidates in the age group are considered “priority 2”. A lung review board (LRB) has authority to adjust scores on appeal for adults and children.

IV. **Rationale**

**Survival**

The Registry of the International Society for Heart and Lung Transplantation (ISHLT) contains data from 42,069 adult recipients who received lung transplantation (including lung retransplantation) before 2012.\(^4\) Reports from 132 transplant centers around the world were obtained on 3640 lung transplants performed in 2011. The overall median survival of patients who underwent lung transplantation between June 1994 and June 2011 was 5.6 years. In the first 30 days after transplantation, the major reported causes of mortality were graft failure and noncytomegalovirus (non-CMV) infections while non-CMV infections became the major cause of death for the remainder of the first year. Beyond the first year, the most common reported causes of mortality were bronchiolitis obliterans, graft failure (lung rejection or bronchiolitis obliterans) and non-CMV infections. Over time, the proportion of patients who died from malignancies increased; malignancies accounted for 15% of all deaths between 5 and 10 years after transplant. Authors of a 2009 review of the current status of lung transplantation observed that while transplantation can prolong survival, survival statistics for lung transplantation are not as favorable as in patients receiving other solid organ transplants.\(^5\)

In 2014, Kistler et al reported on a systematic review of the literature on waitlist and posttransplant survival of idiopathic pulmonary fibrosis.\(^6\) Estimated median survival of idiopathic pulmonary fibrosis patients posttransplantation is estimated at 4.5 years and is lower than other underlying pretransplant diagnoses. From ISHLT and the Organ Procurement and Transplantation Network (OPTN) data, 1-year survival ranged from 75% to 81%; 3-year, 59% to 64%, and 5-year, 47% to 53%. Limited data were available on posttransplant morbidity outcomes.

In 2009, Thabut et al reported on a comparison of patients undergoing single- and double-lung transplantation for idiopathic pulmonary fibrosis.\(^7\) A retrospective review was conducted of 3327 patients with data in the UNOS registry. More patients underwent single-lung compared with
double-lung transplant (64.5% vs 35.5%, respectively). Median survival time was greater for the
double-lung group at 5.2 years (95% confidence interval [CI], 4.3 to 6.7 years) versus 3.8 years
(95% CI, 3.6 to 4.1 years; p<0.001). After adjustment for baseline differences, however, survival
times were not statistically different. The authors concluded that overall survival (OS) did not
differ between the 2 groups: single-lung transplants offered improved short-term survival but
long-term harm, whereas double-lung transplant increased short-term harm but was associated
with a long-term survival benefit. In 2014, Black et al reported on LAS and single versus double
lung transplant in 8778 patients (8050 had an LAS less than 75 and 728 had an LAS 75 or
higher). (8) A significant decrease in survival was seen in single-lung transplant patients with a
high LAS compared with double-lung transplant patients with a high LAS, even though
operative morbidity was higher (p<0.001).

**Patient Selection**

In 2008, Kozower and colleagues performed a retrospective cohort study using data from 5
academic medical centers to evaluate the impact of a new lung allocation score on short-term
outcomes after lung transplantation. (9) (This lung allocation score was implemented in May 2005
by the Organ Procurement and Transplantation Network [OPTN].) This new score changed lung
allocation from a system based on waiting time to an algorithm based on the probability of
survival for 1 year on the transplant list and survival 1-year post-transplantation. Results were
compared for 170 patients who received transplants on the basis of the new lung allocation
scores (May 4, 2005 to May 3, 2006) with those of 171 patients who underwent transplants the
preceding year before implementation of the scoring system. Waiting time decreased from 681 to
445.6 days (p<0.001). Recipient diagnoses changed, with an increase (15% to 25%) in idiopathic
pulmonary fibrosis cases and decreases in emphysema (46% to 34%) and cystic fibrosis (23% to
13%). Hospital mortality and 1-year survival were the same between groups (5.3% vs. 5.3% and
90% vs. 89%, respectively). Presumably due to increased severity of illness, the incidence of
primary graft dysfunction and postoperative intensive care unit length of stay increased in the
year after implementation of the scoring system; graft dysfunction grew from 14.8% (24/170) to
22.9% (39/171); (p=0.04) and length of stay rose from 5.7 to 7.8 days.

In 2010, Yusen and colleagues reviewed the effect of the Lung Allocation Score (LAS) on lung
transplantation by comparing statistics for the period before and after its implementation in
2005. (10) Other independent changes in clinical practice, which may affect outcomes over the
same period of time, include variation in immunosuppressive regimens, an increased supply of
donor lungs, changes in diagnostic mix, and increased consideration of older recipients. Deaths
on the waiting list declined following implementation of the LAS system, from approximately
500 per 5,000 patients to 300 per 5,000 patients. However, it is expected that implementation of
the LAS affected patient characteristics of transplant applicants. One-year survival post-
transplantation did not improve after implementation of the LAS system: patient survival data
before and after are approximately 83%. Long-term survival data are not yet available for
comparison. In 2014 Shafii et al reported on a retrospective evaluation of the LAS and mortality
in 537 adults listed for lung transplantation and 426 who underwent primary lung transplantation
between 2005 and 2010. Patients on the waitlist who had a higher LAS had a higher rate of mortality (p<0.001). In the highest quartile of LAS, ranging from 47 to 95, within 1 year of listing, there was a 75% mortality rate. Higher LAS was also associated with early posttransplant survival (p=0.05) but not late posttransplant survival (p=0.4). When other predictive factors of early mortality were accounted for, pretransplant LAS was not independently related to posttransplant mortality (p=0.12).

Pediatric Considerations

In 2012, Benden et al reviewed pediatric lung transplants that have been reported to the international registry. Pediatric patients are defined as those younger than 18 years of age. The authors noted an increase in the number of pediatric lung transplants in recent years; there were 126 transplants in 2010 compared with 73 in 2000. In contrast to adult patients, the most common indication for pediatric patients was cystic fibrosis, accounting for 54% of lung transplants in 6- to 11-year-olds and 72% of lung transplants in 12- to 17-year-olds that occurred between 1990 and June 2011. Survival has improved in the recent era, and 5-year survival is not significantly different from adult recipients. The half-life, estimated time at which 50% of recipients have died, was 4.7 years for children and 5.3 years for adults. For children receiving allografts between 2002 and June 2010, the 5-year survival rate was 54% and 7-year survival was 44%. Patients aged 1 to 11 years had a significantly better survival rate than those between the ages of 12 and 17 years (half-life of 6.2 years and 4.3 years, respectively). In the first year after lung transplantation, non-CMV infection and graft failure were the 2 leading causes of death. Bronchiolitis obliterans syndrome was the major cause of death beyond 3 years after transplantation.

Potential contraindications

Malignancy

Malignancies are common after lung transplantation with 21% and 40% of patients reporting 1 or more malignancies at 5- and 10-years post-transplantation, respectively. Skin cancer occurred most frequently and lymphoproliferative disorders were the malignancies most associated with morbidity post-transplantation. A 2012 study reported on outcomes in patients with lung cancer who were lung transplant recipients. Ahmad and colleagues identified 29 individuals in the UNOS database who underwent lung transplantation for advanced bronchoalveolar carcinoma (BAC). These patients represented 0.13% of the 21,553 lung transplantations during the study period. BAC and general lung transplant recipients had similar survival rates: the 30-day mortality rate was 7% versus 10% (p=0.44) and 5-year survival rate was 50% versus 57% (p=0.66).

HIV

Solid organ transplant for patients who are human immunodeficiency virus (HIV)-positive has been controversial, due to the long-term prognosis for HIV positivity and the impact of
immunosuppression on HIV disease. Although HIV-positive transplant recipients may be of research interest at some transplant centers, the minimal data regarding long-term outcome in these patients primarily consist of case reports and abstract presentations of liver and kidney recipients. Nevertheless, some transplant surgeons would argue that HIV positivity is no longer an absolute contraindication to transplant due to the advent of highly active antiretroviral therapy (HAART), which has markedly changed the natural history of the disease.

As of October 2013, the Organ Procurement Transplantation Network (OPTN) policy on HIV status in recipients states: “A potential candidate for organ transplantation whose test for HIV is positive should not be excluded from candidacy for organ transplantation unless there is a documented contraindication to transplantation based on local policy.”

In 2006, the British HIV Association and the British Transplantation Society Standards Committee published guidelines for kidney transplantation in patients with HIV disease. These criteria may be extrapolated to other organs:

- CD4 count greater than 200 cells/ml for at least 6 months
- Undetectable HIV viremia (less than 50 HIV-1 RNA copies/ml) for at least 6 months
- Demonstrable adherence and a stable HAART regimen for at least 6 months
- Absence of AIDS-defining illness following successful immune reconstitution after HAART.

Other Infections

Infection with Burkholderia cenocepacia is associated with increased mortality in some transplant centers, a factor that may be taken into account when evaluating overall risk for transplant survival. Two papers published in 2008 evaluated the impact of infection with various species of Burkholderia on outcomes for lung transplantation for cystic fibrosis. In a study published by Murray and colleagues, multivariate Cox survival models assessing hazard ratios (HRs) were applied to 1,026 lung transplant candidates and 528 transplant recipients. Of the transplant recipients, 88 were infected with Burkholderia. Among transplant recipients infected with B cenocepacia, only those infected with nonepidemic strains (n=11) had significantly greater post-transplant mortality than uninfected patients (HR: 2.52; 95% confidence interval [CI]: 1.04-6.12; p=0.04). Transplant recipients infected with Burkholderia gladioli (n=14) also had significantly greater post-transplant mortality than uninfected patients (HR: 2.23; 95% CI: 1.05-4.74; p=0.04). When adjustments for specific species/strains were included, lung allocation scores of Burkholderia multivorans-infected transplant candidates were comparable to uninfected candidate scores, and scores for patients infected with non-epidemic B cenocepacia or B gladioli were lower. In a smaller study of 22 patients colonized with Burkholderia cepacia complex who underwent lung transplantation in two French centers, the risk of death by univariate analysis was significantly higher for the 8 patients infected with B cenocepacia than for the other 14 colonized patients (11 of whom had B multivorans).
In 2012, Shields and colleagues reported on infections in 596 consecutive lung transplant recipients treated at a single center occurring in the first 90 days after transplantation. A total of 109 patients (18%) developed 138 Staphylococcus aureus infections. The most common type of infection was pneumonia (66 of 138, 48%) followed by tracheobronchitis (36 of 138, 26%) and bacteremia (17 of 138, 12%). Thirteen of 109 (12%) patients with S aureus infection died within 90 days of the onset of infection. The 1-year mortality rate was higher for patients with S aureus pneumonia (19 of 66, 29%) but not S aureus tracheobronchitis (8 of 36, 22%) compared with uninfected patients (85 of 487, 17%).

Pinney and colleagues published a retrospective review of invasive fungal infection rates in lung transplantation patients without cystic fibrosis treated at a single center. Patients were followed for a median of 34 months. Invasive fungal infections were identified in 22 of 242 (9.1%) patients. Aspergillus infections were most common, occurring in 11 of 242 (4.5%) of patients. There were also 7 cases (3%) of Candida infection. Survival rates did not differ significantly in patients with invasive fungal infections compared to the entire cohort of patients. For example, 3-year survival was 50% among patients with invasive fungal infection and 66% in the entire cohort, p=0.66. The authors did not compare survival in patients with invasive fungal infections to survival only in those without invasive fungal infections.

In 2013, Lobo and colleagues reported on 13 lung transplant patients with Mycobacterium abscessus in cystic fibrosis. Survival rates were 77%, 64% and 50% after transplant at 1, 3 and 5 years, respectively. These results were not significantly different when compared to 154 cystic fibrosis patients treated with lung transplantation who did not have M abscessus (p=0.8).

**Coronary Artery Disease (CAD)**

Castleberry and colleagues reported on a retrospective cohort study of lung transplantation with concurrent coronary bypass (CAB) or preoperative percutaneous coronary intervention (PCI). Out of 898 lung transplants performed during the period between 1997 and 2010, 49 patients also had concurrent CAB and 38 patients had preoperative PCI. All of the intervention groups, including revascularization, had similar rates of perioperative mortality, overall unadjusted survival and hazard ratio for cumulative risk of death. Postoperative major adverse cardiac event rates were also similar among groups, although postoperative length of stay, intensive care unit time and need for ventilator support increased in patients receiving concurrent CAB with lung transplantation.

In 2011, Sherman and colleagues reported on outcomes in 27 patients with CAD at a single center who underwent lung transplantation and coronary revascularization. Patients needed to be otherwise considered good candidates for transplantation and have discrete coronary lesions (at least 50% in the left main artery or at least 70% in other major vessels) and preserved ejection fraction. Thirteen patients had single-lung transplantation and 14 had double-lung transplantation. Outcomes were compared with a control group of 81 patients without CAD who underwent lung transplantation; patients were matched for age, diagnosis, lung allocation score and type of procedure. During a mean follow-up of 3 years, 9 of 27 (33%) patients with CAD
and 28 of 81 (35%) without CAD died, p=0.91. Bronchiolitis obliterans and infection were the primary causes of death. There was no significant difference between groups in a composite outcome of adverse cardiac events (defined as acute coronary syndrome, redo revascularization or hospital admissions for heart failure), p=0.80.

**Lobar lung transplantation**

Several case series have reported outcomes after lobar lung transplants in both children and adults. In 2005, Barr and colleagues reported on experience performing living donor lobar lung transplants in the U.S. Ninety patients were adults and 43 were children. The primary indication for transplantation (86%) was cystic fibrosis. At the time of transplantation, 67% of patients were hospitalized and 20% were ventilator dependent. Overall recipient actuarial survival at 1, 3 and 5 years was 70%, 54% and 45%, respectively. There was not a statistically significant difference in actuarial survival between adults and children who underwent transplantation. Moreover, survival rates were similar to the general population of lung transplant recipients. The authors also reported that rates of postoperative pulmonary function in patients surviving more than 3 months post-transplant were comparable to rates in cadaveric lung transplant recipients.

In 2014 Date et al reported on a retrospective study comparing 42 living-donor lobar lung transplants and 37 cadaveric lung transplants. Survival rates at 1 and 3 years were not significantly different between the groups (89.7 and 86.1% vs 88.3 and 83.1%, respectively, p=0.55), despite living-donor lobar lung transplant patients having poorer health status preoperatively. In 2012, a program in Japan reported on 14 critically ill patients who had undergone single living-donor lobar lung transplants; there were 10 children and 4 adults. Patients were followed for a mean 45 months. The 3-year survival rate was 70% and the 5-year survival was 56%. Severe graft dysfunction occurred in 4 patients. Mean forced vital capacity (FVC) was found to be lower in patients experiencing severe graft dysfunction compared with the other patients, mean FVC was 54.5% and 66.5%, respectively. The authors stated that this suggests size mismatching in the patients with severe graft dysfunction. Also in 2012, Inci et al published data on 23 patients in Switzerland who received bilateral lobar lung transplants. The mean age was 41 years (range, 13-66). Survival at 1 and 2 years was 82% and 64%, respectively; survival rates were comparable with 219 patients who underwent bilateral lung transplantation during the same time period (p=0.56).

A review article by Date stated that, as of 2011, approximately 400 living-donor lobar lung transplants have been performed worldwide. Procedures in the United States decreased after 2005 due to changes in the lung allocation system. The author stated that size matching between donor and recipient is important and that, to some extent, size mismatching (oversized or undersized grafts) can be overcome by adjusting surgical technique.

In 2014 Slama et al reported on a comparison of outcomes in 138 cadaveric lobar lung transplants (for size discrepancies) to 778 patients who received cadaveric whole-lung transplants, 239 of whom had downsizing by wedge resection of the right middle lobe and/or the
left lingula. Survival in the lobar lung transplant group at 1 and 5 years was 65.1% and 54.9% versus 84.8% and 65.1% in the whole lung and downsized by wedge resection group (p<0.001). The lobar lung transplantation group experienced significantly inferior early postoperative outcomes, but in patients who were successfully discharged, survival rates were similar to standard lung transplantation (p=0.168).

Retransplantation

Registry data and case series reports have demonstrated favorable outcomes with lung retransplantation in certain populations, such as in patients who meet criteria for initial lung transplantation. The ISHLT Registry contains data on 970 retransplantation patients for the period of January 1995 to June 2012 (2.6% of all lung transplantations during this period). Lung retransplantation occurred most commonly for bronchiolitis obliterans syndrome in 568 patients while 402 patients received retransplantation for other reasons. In an analysis of lung transplantation during the period of January 1999 to June 2011, retransplantation was associated with an increased risk of death within 1 year after lung transplantation (HR: 1.69, 95% CI: 1.38–2.07, p<0.0001). However, for patients surviving at least 1 year, the risk of death was no longer associated with retransplantation.

In 2013, Kilic and colleagues evaluated data on 390 adult lung retransplantation patients from the UNOS database. Patients received lung retransplantation during the period May 2005 to December 2010 which was after the LAS selection criteria were implemented. Patients with reduced functional status were found to have poorer outcomes than patients with better functional status prior to retransplantation. Using the Karnofsky scale to stratify patients into functional status groups, the authors found the overall 1-year survival of 56% for patients requiring total assistance before retransplantation was significantly lower than the overall 1-year survival of 82% for patients who only required some assistance before retransplantation (p<0.001). The 1-year mortality rate after risk adjustment was also increased significantly for patients requiring total assistance prior to retransplantation (odds ratio: 3.72, p=0.02). While additional patient selection criteria may be useful for lung retransplantation, current LAS criteria are now used.

Summary of Evidence

The literature on lung and lobar lung transplantation, which consists of case series and registry data, demonstrates that lung and lobar lung transplantation provides a survival benefit in appropriately selected patients and thus may be considered medically necessary. It may be the only option for some patients with end-stage lung disease.

The literature on lung retransplantation is limited but is accumulating in registry data. As in lung transplantation, lung retransplantation may be the only option for patients with failed lung transplantation.
Practice Guidelines and Position Statements

In 2006, the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation published consensus-based guidelines on selection of lung transplant candidates. The guidelines state that:

“Lung transplantation is now a generally accepted therapy for the management of a wide range of severe lung disorders, with evidence supporting quality of life and survival benefit for lung transplant recipients. However, the number of donor organs available remains far fewer than the number of patients with end-stage lung disease who might potentially benefit from the procedure. It is of primary importance, therefore, to optimize the use of this resource, such that the selection of patients who receive a transplant represents those with realistic prospects of favorable long-term outcomes. There is a clear ethical responsibility to respect these altruistic gifts from all donor families and to balance the medical resource requirement of one potential recipient against those of others in their society. These concepts apply equally to listing a candidate with the intention to transplant and potentially de-listing (perhaps only temporarily) a candidate whose health condition changes such that a successful outcome is no longer predicted.”

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

Lung transplantation is covered under Medicare when performed in a facility that is approved by Medicare as meeting institutional coverage criteria. The Centers for Medicare and Medicaid Services have stated that under certain limited cases, exceptions to the facility-related criteria may be warranted if there is justification and the facility ensures safety and efficacy objectives.

V. DEFINITIONS

**BLUE DISTINCTION CENTERS FOR TRANSPLANT (BDCT)** is a cooperative effort of the Blue Cross and Blue Shield Plans, the Blue Cross and Blue Shield Association and participating medical institutions to provide patients who need transplants, with access to leading centers through a coordinated, streamlined program of transplant management.

**CADAVER** refers to a dead body or corpse.

**END-STAGE** refers to the final phase of a disease process.

**LOBE** is a well-defined part of an organ separated by boundaries, especially glandular organs and the brain.
VI. BENEFIT VARIATIONS

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member’s individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member’s benefit information or contact Capital for benefit information.

VII. DISCLAIMER

Capital’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

<table>
<thead>
<tr>
<th>CPT Codes ®</th>
<th>32850</th>
<th>32851</th>
<th>32852</th>
<th>32853</th>
<th>32854</th>
<th>32855</th>
<th>32856</th>
</tr>
</thead>
</table>


<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2060</td>
<td>Lobar lung transplantation</td>
</tr>
<tr>
<td>S2061</td>
<td>Donor lobectomy (lung) for transplantation, living donor</td>
</tr>
<tr>
<td>ICD-10-CM Diagnosis Codes</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>C96.6</td>
<td>Unifocal Langerhans-cell histiocytosis</td>
</tr>
<tr>
<td>D86.0</td>
<td>Sarcoidosis of lung</td>
</tr>
<tr>
<td>D86.2</td>
<td>Sarcoidosis of lung with sarcoidosis of lymph nodes</td>
</tr>
<tr>
<td>E84.0</td>
<td>Cystic fibrosis with pulmonary manifestations</td>
</tr>
<tr>
<td>E84.8</td>
<td>Cystic fibrosis with other manifestations</td>
</tr>
<tr>
<td>E88.01</td>
<td>Alpha-1-antitrypsin deficiency</td>
</tr>
<tr>
<td>I26.01</td>
<td>Pulmonary embolism with acute cor pulmonale</td>
</tr>
<tr>
<td>I26.02</td>
<td>Saddle embolus of pulmonary artery with acute cor pulmonale</td>
</tr>
<tr>
<td>I26.09</td>
<td>Other pulmonary embolism with acute cor pulmonale</td>
</tr>
<tr>
<td>I26.90</td>
<td>Septic pulmonary embolism without acute cor pulmonale</td>
</tr>
<tr>
<td>I26.92</td>
<td>Saddle embolus of pulmonary artery without acute cor pulmonale</td>
</tr>
<tr>
<td>I26.99</td>
<td>Other pulmonary embolism without acute cor pulmonale</td>
</tr>
<tr>
<td>I27.0</td>
<td>Primary pulmonary hypertension</td>
</tr>
<tr>
<td>I27.2</td>
<td>Other secondary pulmonary hypertension (includes pulmonary hypertension due to cardiac disease)</td>
</tr>
<tr>
<td>I27.82</td>
<td>Chronic pulmonary embolism</td>
</tr>
<tr>
<td>I27.89</td>
<td>Other specified pulmonary heart diseases (includes Eisenmenger's syndrome)</td>
</tr>
<tr>
<td>J42</td>
<td>Unspecified chronic bronchitis</td>
</tr>
<tr>
<td>J43.0</td>
<td>Unilateral pulmonary emphysema [MacLeod's syndrome]</td>
</tr>
<tr>
<td>J43.1</td>
<td>Panlobular emphysema</td>
</tr>
<tr>
<td>J43.2</td>
<td>Centrilobular emphysema</td>
</tr>
<tr>
<td>J43.8</td>
<td>Other emphysema</td>
</tr>
<tr>
<td>J44.0</td>
<td>Chronic obstructive pulmonary disease with acute lower respiratory infection</td>
</tr>
<tr>
<td>J44.0</td>
<td>Chronic obstructive pulmonary disease with acute lower respiratory infection</td>
</tr>
<tr>
<td>J44.1</td>
<td>Chronic obstructive pulmonary disease with (acute) exacerbation</td>
</tr>
<tr>
<td>J47.0</td>
<td>Bronchiectasis with acute lower respiratory infection</td>
</tr>
<tr>
<td>J47.1</td>
<td>Bronchiectasis with (acute) exacerbation</td>
</tr>
<tr>
<td>J84.10</td>
<td>Pulmonary fibrosis, unspecified</td>
</tr>
<tr>
<td>J84.112</td>
<td>Idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>J84.17</td>
<td>Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere</td>
</tr>
<tr>
<td>J84.81</td>
<td>Lymphangioleiomyomatosis</td>
</tr>
<tr>
<td>J98.2</td>
<td>Interstitial emphysema</td>
</tr>
<tr>
<td>J98.3</td>
<td>Compensatory emphysema</td>
</tr>
<tr>
<td>M34.81</td>
<td>Systemic sclerosis with lung involvement</td>
</tr>
<tr>
<td>P27.1</td>
<td>Bronchopulmonary dysplasia originating in the perinatal period</td>
</tr>
</tbody>
</table>
**IX. REFERENCES**


survival to cadaveric lung transplantation even for very ill patients dagger. Eur J
Cardiothorac Surg. Sep 16 2014. PMID 25228745
22717276
Oct 2011; 16(5):453-457. PMID 21836512
standard lung transplantation? Transpl Int. Sep 2014; 27(9):909-916. PMID 24810771
2013;96(5):1804-1811. PMID 23968759
21511096
transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific
Council of the International Society for Heart and Lung Transplantation. J Heart Lung
Transplant. 2006;25(7):745-755. PMID
33. Medicare approved lung transplant centers. http://www.cms.gov/Medicare/Provider-
Enrollment-and-
Certification/CertificationandCompliance/downloads/ApprovedTransplantPrograms.pdf

Other:

X. POLICY HISTORY

<table>
<thead>
<tr>
<th>POLICY NUMBER</th>
<th>CAC 7/29/03</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP 9.015</td>
<td>CAC 4/26/05</td>
</tr>
<tr>
<td></td>
<td>CAC 4/25/06</td>
</tr>
<tr>
<td></td>
<td>CAC 4/24/07 Consensus</td>
</tr>
<tr>
<td></td>
<td>CAC 5/27/08 Consensus</td>
</tr>
</tbody>
</table>
## Lung and Lobar Lung Transplant

<table>
<thead>
<tr>
<th>Policy Title</th>
<th>LUNG AND LOBAR LUNG TRANSPLANT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Policy Number</strong></td>
<td>MP-9.015</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date/Revision</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAC 5/26/09 Consensus</td>
<td></td>
</tr>
<tr>
<td>CAC 5/25/10 Consensus</td>
<td></td>
</tr>
<tr>
<td><strong>CAC 4/26/11</strong> Adopted BCBSA. Some transplant indications were removed, however a qualifying statement of “including but not limited to the following indications” was also added. A “medically necessary” statement was added for lobar lung transplant for children and adolescents with end-stage pulmonary disease. A “not medically necessary” statement was added for patients with absolute contraindications.</td>
<td></td>
</tr>
<tr>
<td>CAC 6/26/12 Consensus review; no changes, references updated. FEP variation added.</td>
<td>04/08/13- Codes added to policy</td>
</tr>
<tr>
<td>CAC 7/30/13 Consensus. In lobar lung statement, “children and adolescents” replaced with “carefully selected patients”. No change to intent of policy meaning. Policy guidelines section added – the information was previously included in Background/Description.</td>
<td></td>
</tr>
<tr>
<td>CAC 3/25/14 Minor revision. Policy statement added indicating lung or lobar lung retransplantation may be medically necessary after a failed lung or lobar lung transplant. Policy statement added that lung or lobar lung transplantation is considered investigational in all other situations. References updated. Rationale added.</td>
<td></td>
</tr>
<tr>
<td>CAC 3/24/15 Consensus. No change to policy statements. References and rationale updated. Codes reviewed.</td>
<td></td>
</tr>
<tr>
<td>CAC 3/29/16 Consensus. No change to policy statements. References and rationale reviewed. Coding reviewed.</td>
<td><strong>Admin update 1/1/17:</strong> Product variation section reformatted.</td>
</tr>
</tbody>
</table>